The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Letter to the Editor
In a recent article Dr Tatchell gives a comprehensive review of the pricing of prescription medicines (Aust Prescr 2009;32:6-8). While he addresses issues in the community setting, he fails to include the complexity of prescription pricing in public hospitals.
Access to Pharmaceutical Benefits Scheme (PBS) dispensing was introduced into public hospitals in 2002. While this was intended to parallel the structure in community dispensing, some pricing anomalies exist. Brand price premiums, therapeutic group premiums and special patient contributions do not generally apply. Safety net contributions also differ. Any patient co-payment is added to the patient's safety net, whether for PBS or non-PBS subsidised items. In some hospitals, patient co-payments for non-PBS items are capped at the patient co-payment contribution rate. For example, concession patients pay no more than $5.30 per item, and safety net exemption cardholders may find they are not charged for non-PBS items or even over-the-counter items.
The availability of chemotherapy under the Chemotherapy Pharmaceuticals Access Program1 adds another layer of complexity. Patients can access PBS-subsidised chemotherapy under this program. While they do not pay a co-payment, the actual dollar value of the co-payment (for example, $5.30 per concession patient) is still added to their safety net.
In this era of continuum of care, patients need to be aware that pricing structures differ between the hospital and community setting. Physicians who work in both the public and private sectors must also have an understanding of this pricing anomaly.
Senior Pharmacist, Cancer Services
Robert Mc Lauchlan